Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
|Articles|May 25, 2010
Change for Change
If, when you suggest an improvement, someone in your practice responds, "That's not the way we do things," charge that person 25 cents on the spot.
Advertisement
If, when you suggest an improvement, someone in your practice responds, "That's not the way we do things," charge that person 25 cents on the spot. Collect the money at the end of each quarter and buy ice cream for the staff. That will change some attitudes.
(Courtesy of
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
5